Study Warns on Immunotherapy De-Escalation in Advanced Cancers
(MedPage Today) -- For patients with advanced or metastatic solid tumors who had initial responses to immune checkpoint inhibitors (ICIs), reducing dose intensity did not preserve efficacy, an interim analysis of the MOIO study suggested. For...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.